Your browser doesn't support javascript.
loading
Ulcerative colitis: an update.
Segal, Jonathan P; LeBlanc, Jean-Frédéric; Hart, Ailsa L.
Afiliação
  • Segal JP; Hillingdon Hospital, Uxbridge, UK jonathansegal1@nhs.net.
  • LeBlanc JF; St Mark's Hospital, Harrow, UK.
  • Hart AL; St Mark's Hospital, Harrow, UK and Imperial College London, London, UK.
Clin Med (Lond) ; 21(2): 135-139, 2021 03.
Article em En | MEDLINE | ID: mdl-33762374
ABSTRACT
Ulcerative colitis is a relapsing and remitting disease that is increasing in incidence and prevalence. Management aims to achieve rapid resolution of symptoms, mucosal healing and improvement in a patient's quality of life. 5-aminosalicylate acid medications remain the first-line treatment for mild to moderate disease. In the event of suboptimal response to these medications, escalation to immunosuppressive medications and biologics may be necessary. Importantly, despite best medical therapy, surgery may be required in a proportion of patients. The future will likely see an array of new therapeutic options for those with ulcerative colitis with the potential for a more personalised treatment approach.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Colite Ulcerativa Tipo de estudo: Diagnostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Colite Ulcerativa Tipo de estudo: Diagnostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article